Neurophth to Develop AAV Capsids with AAVnerGene for Ophthalmology

Neurophth Therapeutics of Wuhan partnered with Delaware 's AAVnerGene to develop adeno-associated virus (AAV) capsids for next-gen ophthalmic gene therapies. Neurophth will make an initial cash payment to AAVnerGene to test about 100 AAV capsids. Within 6-12 months, Neurophth will complete preclinical studies on these capsids, and the two companies will select the most promising candidates for further development. AAVnerGene believes its platform selects the best AAV vector for each cell type based on transduction efficiency, immunity to the capsid and best manufacturing processes. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.